Sharan Mahal, MD
Cardiovascular Disease · Bridgewater, NJNPI 1851363360
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,823 of the $9,591 with a category attached, or 81.6%. It is spread thinly across 38 manufacturers, the largest accounting for just 13.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $3,895 and has fallen 73.4% since, to $1,034 in 2025.
Across 372 payments — averaging $25.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim International GmbH$1K
- Boston Scientific$1K
- Bayer$1K
- Amgen$963
- Abiomed$777
- Pfizer$625
- plus $3K from 32 others
Across 1,059 payments — averaging $3321.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$826K
- Janssen Research & Development, LLC$500K
- Boehringer Ingelheim International GmbH$464K
- Novartis$383K
- Boehringer Ingelheim$366K
- Bayer$244K
- plus $735K from 8 others
What the payments were for
- Travel & lodging$1,72818%
- Food & beverage$7,82382%
- Education$400%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim International GmbH | 11 | $1,308 |
| Boston Scientific | 31 | $1,266 |
| Bayer | 11 | $1,234 |
| Amgen | 62 | $963 |
| Abiomed | 18 | $777 |
| Pfizer | 47 | $625 |
| E.r. Squibb & Sons, L.L.C. | 40 | $538 |
| Novartis | 23 | $373 |
| Abbott | 13 | $344 |
| Boehringer Ingelheim | 12 | $290 |
| Johnson & Johnson | 15 | $213 |
| AstraZeneca | 14 | $197 |
| Merck | 10 | $180 |
| Lexicon Pharmaceuticals, Inc. | 7 | $131 |
| Medtronic(2 entities) | 4 | $117 |
| Amarin Pharma, Inc. | 8 | $115 |
| Daiichi Sankyo Inc. | 6 | $98 |
| Irhythm Technologies, Inc. | 2 | $96 |
| Philips North America LLC | 5 | $88 |
| Impulse Dynamics (USA) Inc. | 3 | $71 |
| Heartflow, Inc. | 3 | $65 |
| Sanofi-aventis U.S. LLC | 4 | $59 |
| Cvrx, Inc. | 3 | $59 |
| Shockwave Medical, Inc | 1 | $52 |
| Penumbra, Inc. | 2 | $39 |
| Atricure, Inc. | 1 | $37 |
| Regeneron Healthcare Solutions, Inc. | 3 | $37 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $35 |
| Baxter Healthcare | 1 | $28 |
| United Therapeutics Corporation | 2 | $27 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $21 |
| Cardiovascular Systems Inc. | 1 | $20 |
| Cordis US CORP. | 1 | $19 |
| AbbVie | 1 | $18 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $14 |
| Lilly USA, LLC | 1 | $14 |
| Novo Nordisk | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$342
- AVVIGO Guidance System$264
- WATCHMAN Access System$136
- ELIQUIS$125
- Repatha$104
How this compares
$9,591 in reported general payments places this provider in the 80th percentile of 1,006 cardiovascular disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 306 | $387,481 |
| EntrestoSacubitril/Valsartan | 109 | $143,392 |
| XareltoRivaroxaban | 120 | $127,539 |
| Repatha SureclickEvolocumab | 45 | $56,523 |
| FarxigaDapagliflozin Propanediol | 15 | $13,143 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 23 | $10,559 |
| Ezetimibe | 340 | $8,408 |
| Atorvastatin Calcium | 830 | $8,277 |
| Rosuvastatin Calcium | 579 | $8,212 |
| Ranolazine ErRanolazine | 66 | $6,109 |
| Metoprolol Succinate | 390 | $5,983 |
| ClopidogrelClopidogrel Bisulfate | 354 | $5,231 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 132 | $3,673 |
| Amlodipine Besylate | 399 | $3,098 |
| Nitroglycerin PatchNitroglycerin | 49 | $2,889 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $625 | $387,481306 claims |
| NovartisEntresto | $373 | $143,392109 claims |
| Johnson & JohnsonXarelto | $213 | $127,539120 claims |
| AstraZenecaFarxiga | $197 | $13,14315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,006 cardiovascular disease providers in New Jersey.
Other cardiovascular disease in Bridgewater
- Marc CohenNewark$762K
- Peter FarrugiaColts Neck$600K
- Felix Dailey-SterlingGuttenberg$568K
- Ramzan ZakirNew Brunswick$342K
- Richard KovachBrowns Mills$300K
- Andrea RussoCamden$293K
- John KostisNew Brunswick$225K
- Dilip ViswanathHaddon Heights$167K
- David PowellSpringfield$162K
- Fadi ChaabanWest Orange$161K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.